G. Hannig

发表

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

M. Currie, S. Brierley, L. Blackshaw, 2013, Gastroenterology.

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis.

C. D. Thompson, G. Hannig, S. Bernier, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Experimentally Induced Bladder Permeability Evokes Bladder Afferent Hypersensitivity in the Absence of Inflammation

S. Brierley, G. Hannig, A. Lumsden, 2020, Frontiers in Neuroscience.

Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization

B. Greenwood-Van Meerveld, C. Kurtz, P. Ge, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458.

G. Hannig, S. Bernier, E. Clark, 2007, Arthritis and rheumatism.

Synthesis and evaluation of alkoxy-phenylamides and alkoxy-phenylimidazoles as potent sphingosine-1-phosphate receptor subtype-1 agonists.

A. Saha, G. Hannig, M. Kavarana, 2009, Bioorganic & medicinal chemistry letters.

Linaclotide inhibits colonic and urinary bladder hypersensitivity in adult female rats following unpredictable neonatal stress

B. Greenwood-Van Meerveld, P. Ge, G. Hannig, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Paul E. Miller, R. Feil, S. Brierley, 2018, JCI insight.

Methionine aminopeptidases type I and type II are essential to control cell proliferation

C. D. Thompson, G. Hannig, S. Bernier, 2005, Journal of cellular biochemistry.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

M. Currie, C. Kurtz, G. Hannig, 2010, Life sciences.

A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non–Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo

C. D. Thompson, G. Hannig, M. Labenski, 2006, Clinical Cancer Research.

Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458.

C. D. Thompson, G. Hannig, S. Bernier, 2006, International journal of oncology.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

M. Currie, C. Kurtz, G. Hannig, 2010, European journal of pharmacology.

Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation

M. Currie, E. Ustinova, E. Liong, 2013, PAIN®.

Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

M. Currie, C. Kurtz, G. Hannig, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain.

S. Brierley, J. Castro, A. Harrington, 2021, Trends in pharmacological sciences.

Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscero-visceral cross-talk.

S. Brierley, J. Castro, A. Harrington, 2019, Pain.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux

M. Currie, C. Lunte, C. Kurtz, 2015, The Journal of Pharmacology and Experimental Therapeutics.

MRP 4 Modulation of the Guanylate Cyclase-C / cGMP Pathway : Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux s

M. Currie, C. Lunte, C. Kurtz, 2015 .

Pharmacological Properties, Metabolism and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation #

C. Kurtz, G. Hannig, D. James, 2012 .

An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis

C. D. Thompson, A. Rogers, G. Hannig, 2008, Inflammation Research.

366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation

Lin Chang, S. Brierley, C. Kurtz, 2016 .

The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes

J. Masferrer, P. Ge, G. Hannig, 2016, Investigative ophthalmology & visual science.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain

M. Currie, C. Kurtz, G. Hannig, 2014, Front. Mol. Neurosci..

Linaclotide activates guanylate cyclase‐C/cGMP/protein kinase‐II‐dependent trafficking of CFTR in the intestine

G. Hannig, I. Silos-santiago, B. Tchernychev, 2017, Physiological reports.

Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists.

A. Saha, G. Hannig, A. Satz, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists.

A. Saha, G. Hannig, A. Satz, 2009, Bioorganic & medicinal chemistry letters.

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Jordi Villà-Freixa, Peter Sandner, Bernd J. Pichler, 2017, BMC Pharmacology and Toxicology.

Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules*

A. C. Sen, V. Reinhold, G. Hannig, 1999, The Journal of Biological Chemistry.

Peripheral Guanylate Cyclase‐C modulation of corticolimbic activation and corticotropin‐releasing factor signaling in a rat model of stress‐induced colonic hypersensitivity

B. Greenwood-Van Meerveld, G. Hannig, C. Ligon, 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Guanylate cyclase 2C agonism corrects CFTR mutants.

J. Clancy, M. Helmrath, Nambirajan Sundaram, 2017, JCI insight.

Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2.

C. D. Thompson, G. Hannig, C. Arico-Muendel, 2009, Journal of medicinal chemistry.

Mo1515 - Bile Acid Sequestrant Shows Effects on the Contractile Activity of Ex Vivo Lower Esophageal Sphincter Muscle

M. Currie, G. Hannig, A. Silos-Santiago, 2018 .

Reversible tyrosine phosphorylation and cell cycle control.

H. Piwnica-Worms, G. Hannig, S. Atherton-Fessler, 1993, Seminars in cell biology.

Comparison of the biochemical and biological functions of tyrosine phosphatases from fission yeast, budding yeast and animal cells

R. Erikson, G. Hannig, A. Schievella, 1993, Yeast.

Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications

James C. Campbell, Dong I. Lee, M. Zaccolo, 2017, BMC Pharmacology and Toxicology.

A tightly regulated high level expression vector that utilizes a thermosensitive lac repressor: production of the human T cell receptor V beta 5.3 in Escherichia coli.

P. Ford, G. Hannig, B. Andrews, 1996, Gene.

M. Schartl, A. Barnekow, G. Hannig, 1992, Oncogene.

Strategies for optimizing heterologous protein expression in Escherichia coli.

G. Hannig, G Hannig, S C Makrides, 1998, Trends in biotechnology.

Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.

Paul E. Miller, R. Feil, S. Brierley, 2018, JCI insight.